Literature DB >> 23430671

Risk factors influencing mortality related to Stenotrophomonas maltophilia infection in hematology-oncology patients.

Hayati Demiraslan1, Mustafa Sevim, Çiğdem Pala, Süleyman Durmaz, Veli Berk, Leylagül Kaynar, Gökhan Metan.   

Abstract

Stenotrophomonas maltophilia infection is of concern in patients with cancer. Antibiotics active against S. maltophilia are rarely used in the treatment of febrile neutropenia, making it important to identify the factors influencing mortality in cancer patients with S. maltophilia infection. The objective of this study was to analyze the clinical characteristics and outcomes of cancer and hemopathic patients with S. maltophilia infection and assess the factors influencing the mortality. The microbiology laboratory records of Erciyes University, Faculty of Medicine Hospital were reviewed to retrospectively identify patients with S. maltophilia infection between January 2007 and June 2011. A total of 38 patients (25 male, 13 female) were eligible for the study. The median age of the patients was 53 years. The underlying disease was hematological malignancy and disorders in 76.3 % (29 cases), solid tumors in 15.8 % (six cases), aplastic anemia in 7.9 % (three cases), while 18.4 % (seven cases) were hematopoietic stem cell transplantation (HSCT) recipients. An indwelling central venous catheter was used in 32 cases (84.2 %). Twenty-seven patients (71.1 %) were neutropenic at the onset of infection. Nine patients (23.7 %) were receiving corticosteroid therapy. The overall 14-day mortality rate was 50 %. Three of the patients received empirical antibacterial treatment, and three HSCT recipients received trimethoprim-sulfamethoxazole prophylaxis, which is active against S. maltophilia. Severe sepsis (OR 13.24, 95 % confidence interval (CI) 1.62-108.57) and the duration of the treatment (OR 0.73, 95 % CI 0.60-0.90) were related to death based on logistic regression analysis findings. In immunocompromised hematology-oncology patients with severe sepsis, S. maltophilia should be considered as a possible cause of infection, and should be given effective empirical antibiotic treatment immediately; the antimicrobial spectrum may be narrowed according to results of antibiotic susceptibility test.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23430671     DOI: 10.1007/s12185-013-1296-x

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  34 in total

1.  Risk factors for mortality among patients with Stenotrophomonas maltophilia bacteremia in Tokyo, Japan, 1996-2009.

Authors:  H Araoka; M Baba; A Yoneyama
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-02-23       Impact factor: 3.267

2.  Impact of initial antimicrobial therapy in patients with bloodstream infections caused by Stenotrophomonas maltophilia.

Authors:  Gokhan Metan; Omrum Uzun
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

3.  Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997-1999).

Authors:  A C Gales; R N Jones; K R Forward; J Liñares; H S Sader; J Verhoef
Journal:  Clin Infect Dis       Date:  2001-05-15       Impact factor: 9.079

Review 4.  2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference.

Authors:  Mitchell M Levy; Mitchell P Fink; John C Marshall; Edward Abraham; Derek Angus; Deborah Cook; Jonathan Cohen; Steven M Opal; Jean-Louis Vincent; Graham Ramsay
Journal:  Crit Care Med       Date:  2003-04       Impact factor: 7.598

Review 5.  Definitions of cytomegalovirus infection and disease in transplant recipients.

Authors:  Per Ljungman; Paul Griffiths; Carlos Paya
Journal:  Clin Infect Dis       Date:  2002-03-11       Impact factor: 9.079

Review 6.  Stenotrophomonas maltophilia: an emerging global opportunistic pathogen.

Authors:  Joanna S Brooke
Journal:  Clin Microbiol Rev       Date:  2012-01       Impact factor: 26.132

7.  Predictors of catheter-related gram-negative bacilli bacteraemia among cancer patients.

Authors:  J Cairo; R Hachem; G Rangaraj; B Granwehr; I Raad
Journal:  Clin Microbiol Infect       Date:  2011-05-20       Impact factor: 8.067

8.  Risk factors for Stenotrophomonas maltophilia bacteremia in oncology patients: a case-control study.

Authors:  Anucha Apisarnthanarak; Jennie L Mayfield; Teresa Garison; Patricia M McLendon; John F DiPersio; Victoria J Fraser; Louis B Polish
Journal:  Infect Control Hosp Epidemiol       Date:  2003-04       Impact factor: 3.254

9.  Stenotrophomonas maltophilia: an emerging opportunist human pathogen.

Authors:  W John Looney; Masashi Narita; Kathrin Mühlemann
Journal:  Lancet Infect Dis       Date:  2009-05       Impact factor: 25.071

10.  Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group.

Authors:  Ben De Pauw; Thomas J Walsh; J Peter Donnelly; David A Stevens; John E Edwards; Thierry Calandra; Peter G Pappas; Johan Maertens; Olivier Lortholary; Carol A Kauffman; David W Denning; Thomas F Patterson; Georg Maschmeyer; Jacques Bille; William E Dismukes; Raoul Herbrecht; William W Hope; Christopher C Kibbler; Bart Jan Kullberg; Kieren A Marr; Patricia Muñoz; Frank C Odds; John R Perfect; Angela Restrepo; Markus Ruhnke; Brahm H Segal; Jack D Sobel; Tania C Sorrell; Claudio Viscoli; John R Wingard; Theoklis Zaoutis; John E Bennett
Journal:  Clin Infect Dis       Date:  2008-06-15       Impact factor: 9.079

View more
  8 in total

1.  Can levofloxacin be a useful alternative to trimethoprim-sulfamethoxazole for treating Stenotrophomonas maltophilia bacteremia?

Authors:  Sun Young Cho; Cheol-In Kang; Jungok Kim; Young Eun Ha; Doo Ryeon Chung; Nam Yong Lee; Kyong Ran Peck; Jae-Hoon Song
Journal:  Antimicrob Agents Chemother       Date:  2013-10-14       Impact factor: 5.191

2.  Clinical Characteristics, Outcomes, and Risk Factors for Mortality in Patients with Stenotrophomonas maltophilia Bacteremia.

Authors:  Siripen Kanchanasuwan; Jakkapan Rongmuang; Pisud Siripaitoon; Narongdet Kositpantawong; Boonsri Charoenmak; Thanaporn Hortiwakul; Ozioma Forstinus Nwabor; Sarunyou Chusri
Journal:  J Clin Med       Date:  2022-05-30       Impact factor: 4.964

Review 3.  The growing threat of multidrug-resistant Gram-negative infections in patients with hematologic malignancies.

Authors:  Thomas M Baker; Michael J Satlin
Journal:  Leuk Lymphoma       Date:  2016-06-24

Review 4.  The current spectrum of infection in cancer patients with chemotherapy related neutropenia.

Authors:  Lior Nesher; Kenneth V I Rolston
Journal:  Infection       Date:  2013-08-23       Impact factor: 3.553

Review 5.  New Insight on Epidemiology and Management of Bacterial Bloodstream Infection in Patients with Hematological Malignancies.

Authors:  Sara Lo Menzo; Giulia la Martire; Giancarlo Ceccarelli; Mario Venditti
Journal:  Mediterr J Hematol Infect Dis       Date:  2015-07-01       Impact factor: 2.576

6.  Risk factors for mortality in patients with Stenotrophomonas maltophilia bacteremia.

Authors:  Yong Duk Jeon; Woo Yong Jeong; Moo Hyun Kim; In Young Jung; Mi Young Ahn; Hea Won Ann; Jin Young Ahn; Sang Hoon Han; Jun Yong Choi; Young Goo Song; June Myung Kim; Nam Su Ku
Journal:  Medicine (Baltimore)       Date:  2016-08       Impact factor: 1.889

7.  Predictive implications of albumin and C-reactive protein for progression to pneumonia and poor prognosis in Stenotrophomonas maltophilia bacteremia following allogeneic hematopoietic stem cell transplantation.

Authors:  Kaito Harada; Noritaka Sekiya; Tatsuya Konishi; Akihito Nagata; Yuta Yamada; Toshiaki Takezaki; Satoshi Kaito; Shuhei Kurosawa; Masahiro Sakaguchi; Shunichiro Yasuda; Shugo Sasaki; Kosuke Yoshioka; Kyoko Watakabe-Inamoto; Aiko Igarashi; Yuho Najima; Takeshi Hagino; Hideharu Muto; Takeshi Kobayashi; Noriko Doki; Kazuhiko Kakihana; Hisashi Sakamaki; Kazuteru Ohashi
Journal:  BMC Infect Dis       Date:  2017-09-22       Impact factor: 3.090

8.  Predictors of 7- and 30-day mortality in pediatric intensive care unit patients with cancer and hematologic malignancy infected with Gram-negative bacteria.

Authors:  Patrícia de Oliveira Costa; Elias Hallack Atta; André Ricardo Araujo da Silva
Journal:  Braz J Infect Dis       Date:  2014-07-19       Impact factor: 3.257

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.